IMPORTANCE Androgen deprivation therapy (ADT) improves survival outcomes in patients with high-risk prostate cancer (PCa) treated with radiotherapy (RT). Whether this benefit differs between patients with Gleason grade group (GG) 4 (formerly Gleason score 8) and GG 5 (formerly Gleason score 9-10) disease remains unknown.
M ultiple randomized clinical trials have demonstrated a survival benefit to combining longduration androgen deprivation therapy (ADT) with radiotherapy (RT) for high-risk prostate cancer (PCa).
1 Androgen deprivation therapy has multiple adverse effects 2 and several trials have investigated shortening ADT duration. Although most trials conflate the outcomes for patients with Gleason grade group (GG) 4 (formerly Gleason score 8) and GG 5 (formerly Gleason score 9-10) disease, GG 5 PCa has been consistently shown to follow a more aggressive natural history, and the effect of ADT duration might differ between the two. 3 To identify differences in the association of ADT duration with clinical outcomes of patients with GG 4 and GG 5 PCa, we performed an individual patient-level meta-analysis of 6 randomized clinical trials ( Table 1) . 4-9 Our working hypothesis was that longer durations of ADT would offer significant survival benefits in both groups.
Methods
Details of trial selection and specific trial information are provided in eFigure 1 and eTable 1 in the Supplement. Long-term ADT (LTADT) was defined as 28 to 36 months, whereas shortterm ADT (STADT) was defined as 4 to 6 months. The primary endpoints were distant metastasis-free survival (DMFS), cancer-specific survival (CSS), and overall survival (OS). For DMFS and OS, patient-level data were used to obtain trial-specific hazard ratio (HR) estimates of pairwise treatment effects after fitting multivariable Cox proportional hazards models adjusting for age, specific Gleason score (eg, 9 vs 10), interaction of treatments and GG, and T-stage. For CSS, HRs were obtained by fitting cause-specific competing risk models with competing events, such as noncancer-related deaths treated as censored observations. For studies with small sample size, Firth's bias correction method 10 was applied in the estimation of individual models to obtain stable estimates. A network meta-analysis (NMA) 10,11 approach was adopted for direct/ indirect pairwise meta-analysis of treatments. Based on novel graph-theory methodology and electrical networks, this frequentist method derives an NMA framework that enables incorporation of indirect comparisons constructed from 2 studies that have 1 treatment in common, while accounting for the correlated treatment effects in multiarm trials (eFigure 2 in the Supplement). 11 Fixed-effect and random-effects models were adopted after evaluating the heterogeneity and inconsistency of the included studies by between-studies variance, percentage of the total variability in a set of effect sizes owing to true heterogeneity, and Q test for heterogeneity/inconsistency, and treatments were ranked by P score, a frequentist analogue to the surface under the cumulative ranking curve.
Traditional random-effects meta-analyses were performed to compare outcomes between GG 5 and GG 4 disease as a function of ADT duration. All statistical analyses were conducted using SAS statistical software (version 9.4, SAS Institute Inc) and Packages "netmeta" (Network Meta-Analysis using Frequentist Methods) and "meta" in the R statistical software environment (version 3.3.1, R Foundation).
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Results
Five hundred ninety-three male patients (mean age, 70 years; range, 43-88 years) with GG 4 and 399 with GG 5 were identified, with a median follow-up of 6.4 years. Baseline characteristics and clinical outcome are provided in Table 2 and eTable 2 in the Supplement. Individual trial Cox proportional hazard models for DMFS, CSS, and OS suggested variable effects between GG 4 and GG 5 patients (eTable 3 in the Supplement). The NMA found that among patients with GG 4 disease, both LTADT and STADT offered improved OS over RT alone (HR, 0.43; 95% CI, 0.26-0.72 and HR, 0.59; 95% CI, 0.38-0.93, respectively; P = .02 for both), whereas lifelong ADT did not (HR, 0.84; 95% CI, 0.54-1.30; P = .44) (Figure) 4-9 (eFigure 3 and eTable 4 in the Supplement). Among patients with GG 5 disease, lifelong ADT improved OS (HR, 0.48; 95% CI, 0.31-0.76; P = .01), whereas neither LTADT nor STADT did (HR, 0.80; 95% CI, 0.45-1.44 and HR, 1.13; 95% CI, 0.69-1.87; P = .45 and P = .64, respectively). Forest plot analyses of outcomes from traditional randomeffects meta-analyses comparing GG 4 and GG 5 patients are shown in the Figure and in eFigure 4 in the Supplement. Both among patients receiving STADT and among all patients overall (regardless of ADT duration), those with GG 5 disease had inferior OS compared with those with GG 4 disease (HR, 1.40; 95% CI, 1.05-1.88; P = .05 for STADT and HR, 1.25; 95% CI, 1.07-1.47; P = .04 all patients). Among patients receiving LTADT or lifelong ADT, there was no significant difference in OS between GG 5 and GG 4 disease (HR, 1.21; 95% CI, 0.89-1.65 and HR, 0.85; 95% CI, 0.53-1.37; P = .23 and P = .52, respectively).
Discussion
In this individual patient-level meta-analysis, longer durations of ADT were found to improve clinical outcomes for patients with GG 4 and GG 5 disease in distinct ways. Among patients with GG 4 disease, both LTADT and STADT offered improved OS over RT alone, whereas lifelong ADT did not. Among patients with GG 5 disease, lifelong ADT improved OS over RT alone, whereas neither LTADT nor STADT did. Overall, and among patients receiving STADT, GG 5 disease was associated with worse OS; LTADT and lifelong ADT appear to mitigate this difference. Similar patterns were seen for DMFS and CSS endpoints, though these endpoints contained more uncertainty than the OS endpoint owing to potential misclassification. These results also provide prospectively obtained evidence that patients with GG 5 disease receiving RT have inferior outcomes compared with those with GG 4 disease.
Androgen deprivation therapy may improve outcomes in RT-treated patients with high-risk PCa through a combination of systemic effects on micrometastatic disease and direct radiosensitizing effects in the prostate, 12 and adjuvant ADT has been shown to suppress the induction of androgen receptoracti vi tyb yR T . 13 If GG 5 PCa has greater RT induction of androgen receptor activity than GG 4 disease, a longer period of adjuvant ADT would be required for a similar therapeutic effect, explaining the clear benefit of lifelong ADT in treating GG 5 disease. The lack of any significant survival benefit for lifelong ADT in treating GG 4 disease may reflect a lack of statistical power; for CSS and DMFS, it may also reflect the relative uncertainty of these endpoints. Alternatively, the known sequelae of lifelong ADT may counteract any potential oncologic benefit, potentially explaining the lack of an OS benefit. The lack of benefit for any outcome with LTADT in GG 5 disease might suggest that the magnitude of the benefit may have been too small to detect even with a meta-analysis. A multi-institutional analysis of GG 5 patients identified a significant CSS benefit to extreme dose escalation with a brachytherapy boost over standard dose-escalated RT, despite a significantly longer ADT duration with standard doseescalated RT.
14 Although this might suggest that less radiosensitizing ADT is required with higher RT doses, the median duration of ADT with extreme dose escalation was still 12 months, and the study was retrospective. Finally, a recent randomized trial comparing 18 months of ADT with 36 months of ADT for high-risk PCa did not identify a difference in survival outcomes with longer duration ADT. 9 However, were data from this trial to be incorporated into the present meta-analysis, patients receiving 18 months of ADT would likely be considered as having received an intermediate duration between LTADT and STADT, rather than receiving STADT.
Limitations
There are several limitations to this study. Foremost, this constitutes an unplanned subset analysis of multiple randomized clinical trials, and thus the findings must be interpreted with the knowledge that none of the trials were specifically powered or designed to evaluate differences in outcome based on GG. 15 Limitations include a lack of centralized pathology review, the use of radiation doses that would be considered substandard today, and the high enrichment of patients with locally advanced lesions compared with modern cohorts (66% with cT3 disease). Regarding pathology review, this is a limitation with regard to concordance between studies but also, owing to changes in the Gleason grading system over time, may Forest plot derived from network meta-analysis of ADT effect on all-cause mortality, stratified by (A) GG 4 vs (B) GG 5. Note that the reference value (HR 1.00) for each forest plot is radiation therapy (RT) alone. The hazard ratios (HRs) and 95% confidence intervals (95% CI) are presented in ascending order, with their associated P-score (a frequentist analog to the surface under the cumulative ranking curve). C, Forest plot derived from meta-analysis of association of GG 4 vs GG 5 with all-cause mortality, stratified by ADT duration. HRs and 95% CI for each ADT duration stratum are presented, along with corresponding treatment effect (TE; log [HR] ) and the standard error of the TE (seTE).
affect the applicability of these findings to GG 4 and GG 5 PCas diagnosed in the present day. However, all of these limitations apply to the general applicability of these trials to the modern era, yet they still define the present standard of care. In addition, the most robust effect noted is that of lifelong ADT in the GG 5 group and was observed in a trial initiated 31 years ago in which staging studies were relatively insensitive. It is possible that the benefit of lifelong ADT might come primarily from controlling occult metastases, rather than reflecting the biology of the primary disease. However, this would be expected to be true for patients with GG 4 disease as well, and lifelong ADT did not offer a statistically significant benefit in those patients. Finally, the studies varied in the use of concurrent nonsteroidal anti-androgens in conjunction with luteinizing hormone releasing hormone agonists, as well as the timing of initiation of ADT.
Conclusions
Prolonged durations of ADT improve survival outcomes in both GG 4 disease and GG 5 disease, albeit in different ways. Use of STADT and LTADT offer OS improvements in GG 4 disease, but not GG 5 disease; the opposite is true for lifelong ADT. Strategies to maintain the efficacy of ADT while minimizing its duration (eg, enhanced potency agents) should be investigated. 
